© REUTERS/Leonhard Foeger
Hætteglas med AstraZenecas COVID-19-vaccine ses i en almindelig lægepraksis hos en læge, da spredningen af ​​coronavirus-sygdommen (COVID-19) fortsætter i Wien, Østrig 30. april 2021.
Europas lægemiddelregulator gennemgår rapporter om en sjælden nervedegenererende lidelse hos mennesker, der fik AstraZenecas (AZN.L) COVID-19 indspøjtninger, hvilket rejser nye spørgsmål om potentielle bivirkninger af vaccinen.

Som en del af en regelmæssig gennemgang af sikkerhedsrapporter for vaccinen analyserer Vaxzevria, sikkerhedsudvalget for Det Europæiske Lægemiddelagentur (EMA) data fra AstraZeneca om tilfælde af Guillain-Barre syndrom (GBS), sagde det fredag ​​uden angivelse af antallet af sager.

Den engelsk-svenske lægemiddelproducent reagerede ikke straks på en anmodning om kommentar.

The move comes after the EMA found last month that COVID-19 vaccines from both AstraZeneca and Johnson & Johnson (JNJ.N) may have caused very rare blood clotting cases.

While the regulator has said the benefits of AstraZeneca's cheap and easily transportable vaccine in fighting the deadly pandemic outweigh any risks, several European countries have limited use to older age groups or suspended use altogether.

The EMA has also backed J&J's vaccine, which is based on a similar technology to AstraZeneca's.

The regulator said GBS was identified as a possible adverse event that needed to be specifically monitored during the vaccine's conditional approval process, adding it had requested more detailed data on the cases from AstraZeneca.


GBS is a rare neurological condition in which the body's immune system attacks the protective coating on nerve fibres. Most cases follow a bacterial or viral infection.

The condition has been linked in the past to vaccinations - most notably to a vaccination campaign during a swine flu outbreak in the United States in 1976, and decades later to the vaccine used during the 2009 H1N1 flu pandemic.

However, researchers have found the chances of developing GBS after vaccination are extremely small.

Comment: Are recipients made aware of this risk, however small, considering that this could irrevocable ruin their health? More so considering the chances of the vast majority of suffering any long lasting ill effects of the coronavirus are vanishingly small.

On Friday, the EMA also said it was looking into reports of heart inflammation with Pfizer-BioNTech's (PFE.N), (22UAy.DE) vaccine and Moderna's (MRNA.O) shot. It said there was no indication at present that these cases were due to the vaccines.

Both the Pfizer-BioNTech and Moderna vaccines use new mRNA technology to build immunity.

Last week, the U.S. Centers for Disease Control and Prevention said it had not found a link between heart inflammation and COVID-19 vaccines.

Pfizer and BioNTech said in a joint statement they would support the EMA's review and that they also saw no indication of a causal link after more than 450 million doses had been administered globally.

Myocarditis was not observed at a higher rate than would be expected in the general population, they added.

Moderna did not immediately respond to a request for comment.